Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Two-cycle, Single Sequence, Self-controlled Study Evaluating Effects of Oral Itraconazole or Efavirenz on Pharmacokinetic Profiles of TGRX-326

NCT06294561 is registered in ClinicalTrials.gov with Shenzhen TargetRx Co., Ltd. as lead sponsor.

NCT NCT06294561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06294561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Two-cycle, Single Sequence, Self-controlled Study Evaluating Effects of Oral Itraconazole or Efavirenz on Pharmacokinetic Profiles of TGRX-326
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 4, 2024
Completion date
May 6, 2024
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer